Condition (MeSH)
Optic Nerve Glioma
ClinicalTrials.gov lists 82 trials for Optic Nerve Glioma or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 25.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
82 of the 82 trials are tagged with Optic Nerve Glioma itself; the rest are tagged with a narrower condition beneath it.
When did Optic Nerve Glioma trials start? (26)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 3
- Not applicable
- Observational
Top of scale: 10
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2022 | 1 |
| 2019 | 1 |
| 2018 | 1 |
| 2017 | 2 |
| 2015 | 3 |
| 2014 | 1 |
| 2013 | 4 |
| 2012 | 1 |
| 2011 | 2 |
| 2010 | 4 |
Showing 10 of 26 earlier years.
No forecast is made for this condition: it averages 0.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Optic Nerve Glioma trials in? (6)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 46 |
| Phase 1/2 | 4 |
| Phase 2 | 17 |
| Phase 3 | 3 |
| Not applicable | 4 |
| Observational | 8 |
How many Optic Nerve Glioma trials are recruiting? (6)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 2 |
| Active, not recruiting | 2 |
| Completed | 59 |
| Terminated | 11 |
| Withdrawn | 4 |
Showing 5 of 6 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Optic Nerve Glioma trials? (5)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Cancer Institute (NCI) | 25 |
| Children's Oncology Group | 12 |
| Pediatric Brain Tumor Consortium | 8 |
| National Institutes of Health Clinical Center (CC) | 3 |
| Daiichi Sankyo | 1 |
Which drugs are being tested for Optic Nerve Glioma? (3)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Irinotecan | 4 |
| O6-Benzylguanine | 3 |
| Busulfan | 3 |
Interventions as named in the registry (12)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| or carboplatin | 12 |
| SOC: Temozolomide | 11 |
| Filgrastime (G-CSF) | 8 |
| Etoposid | 7 |
| Radiation Therapy | 6 |
Showing 5 of 12 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Optic Nerve Glioma trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Fever | 8 | 3 |
| Hydrocephalus | 8 | 2 |
| Neutrophil count decreased | 7 | 1 |
| Hypokalemia | 6 | 3 |
| Seizure | 6 | 3 |
Showing 5 of 10 adverse events.
Which publications cover Optic Nerve Glioma? (9)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Precocious Puberty in Children with Neurofibromatosis Type 1. | The Journal of pediatrics | 2025 | Yes |
| Nerve growth factor improves visual loss in childhood optic gliomas: a randomized, double-blind, phase II clinical trial. | Brain : a journal of neurology | 2016 | Yes |
| Functional outcome measures for NF1-associated optic pathway glioma clinical trials. | Neurology | 2013 | Yes |
| Nerve growth factor eye drop administration improves visual function in a patient with optic glioma. | Neurorehabilitation and neural repair | 2011 | Yes |
| Topical nerve growth factor as a visual rescue strategy in pediatric optic gliomas: a pilot study including electrophysiology. | Neurorehabilitation and neural repair | 2011 | Yes |
Showing 5 of 9 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.